

VIII

wherein:

Z' is selected from the group of –OH, $-OC(O)R^3$, $-OCO_2R^3$, and $-OC(O)SR^3$;

D^4 and D^3 are independently selected from the group of –H, alkyl, $-OR^2$, –OH, and $-OC(O)R^3$;

with the proviso that at least one of D^4 and D^3 are –H;

R^2 is selected from the group of R^3 and H;

R^3 is selected from the group of alkyl, aryl, alicyclic, and aralkyl;

wherein said compound of formula I is converted to MPO_3H_2 by human liver microsomes, with the proviso that MPO_3^{2-} is not an FBPase inhibitor;

and pharmaceutically acceptable prodrugs and salts of Formula VIII;

and a pharmaceutically acceptable excipient.--

D' Cont'd

REMARKS

Claims 2-13 are pending. Upon the entry of this amendment, claims 2-19 will be pending. Support for these new claims can be found throughout the specification, for instance at pp. 49-51 and p. 56.

Respectfully Submitted,

Date: 3/27/02

By: Jessica R. Wolff
Reg. No. 37,261

Brobeck, Phleger & Harrison LLP
12390 El Camino Real
San Diego, CA 92130-2081
Direct Dial: (858)720-2500
Facsimile: (858)720-2555